Shuttle Pharmaceuticals Holdings closed at $5.15 on Nov 3, up 4.04%, 89.5% below its 52-week closing high. Volume of 54.6K shares was 1.12× its 20-day average (close to normal).
Split-adjusted performance: +28.4% over one month, -34.7% over six months, -82.7% over one year.
Short interest was 31.3K shares at the Oct 15 settlement, up 76.0% from the prior report (3.1% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SHPHShuttle Pharmaceuticals Holdings | $5.15 | +4.04% | −34.7% | — | — | — | $24.5M | |
| BYSIBeyondSpring | $0.6210 | −22.94% | −56.9% | — | — | — | $25.5M | Compare |
| CRVOCervoMed | $1.55 | −5.49% | −58.4% | −100.0% | — | — | $23.4M | Compare |
| ATOSAtossa Therapeutics | $2.33 | +1.30% | −58.2% | — | — | — | $23.3M | Compare |
| IMNNImunon | $0.9000 | +3.44% | −67.5% | — | — | — | $23.1M | Compare |
| CPHIChina Pharma Holdings | $0.6092 | +0.48% | +10.3% | −7.5% | −153.8% | — | $26.2M | Compare |
| BCTXBriacell Therapeutics | $3.01 | −2.59% | −26.0% | — | — | — | $26.3M | Compare |
| ABVCABVC BioPharma | $0.9851 | +0.51% | −4.4% | — | — | — | $26.3M | Compare |
| CELUCelularity | $0.8171 | +1.82% | −14.3% | −5.3% | 10.1% | — | $26.5M | Compare |
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
